18
Participants
Start Date
May 1, 2023
Primary Completion Date
December 31, 2025
Study Completion Date
December 31, 2025
Biological: narsoplimab
Treatment with narsoplimab 4 mg/kg will be administered
NOT_YET_RECRUITING
Omeros Investigational Site, New York
RECRUITING
Omeros Investigational Site, Valhalla
NOT_YET_RECRUITING
Omeros Investigational Site, Gainesville
RECRUITING
Omeros Investigational Site, St Louis
NOT_YET_RECRUITING
Omeros Investigational Site, Houston
RECRUITING
Omeros Investigational Site, San Diego
NOT_YET_RECRUITING
Omeros Investigational Site, Seattle
NOT_YET_RECRUITING
Omeros Investigational Site, Boston
NOT_YET_RECRUITING
Omeros Investigational Site, Halle
NOT_YET_RECRUITING
Omeros Investigational Site, Hanover
NOT_YET_RECRUITING
Omeros Investigational Site, Haifa
NOT_YET_RECRUITING
Omeros Investigational Site, Jerusalem
NOT_YET_RECRUITING
Omeros Investigational Site, Ramat Gan
NOT_YET_RECRUITING
Omeros Investigational Site, Tel Aviv
NOT_YET_RECRUITING
Omeros Investigational Site, Utrecht
RECRUITING
Omeros Investigational Site, Pamplona
Lead Sponsor
Omeros Corporation
INDUSTRY